The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice
Authors:
- Anna Maria MalfitanoAnna Maria Malfitano
- Chiara LaezzaCLChiara Laezza
- Mario GalganiMGMario Galgani
- Giuseppe MatareseGMGiuseppe Matarese
- Alba D’aLessandroADAlba D’aLessandro
- Patrizia GazzerroPGPatrizia Gazzerro
- Maurizio BifulcoMBMaurizio Bifulco
- 1 March 2012
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 65 (3) , 365-371
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitationPharmacological Research, 2009
- Activation of the Peripheral Endocannabinoid System in Human ObesityDiabetes, 2005
- Rimonabant: The first therapeutically relevant cannabinoid antagonistLife Sciences, 2005
- The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balanceThe FASEB Journal, 2005
- Endocannabinoid control of food intake and energy balanceNature Neuroscience, 2005
- A new strategy to block tumor growth by inhibiting endocannabinoid inactivationThe FASEB Journal, 2004
- Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2003
- Appetite suppression and weight loss after the cannabinoid antagonist SR 141716Life Sciences, 1998
- Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonistLife Sciences, 1995
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 1994